Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism

Hypertension

Volumn 63, Issue 4, 2014, Pages 783-789

  Murthy, Meena ^a   Xu, Shengxin ^b   Massimo, Gianmichele ^a   Wolley, Martin ^b   Gordon, Richard D ^b   Stowasser, Michael ^b   O'Shaughnessy, Kevin M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

adrenal cortex; KCNJ5 potassium channel; mutation missense; polymorphism single nucleotide

Indexed keywords

DNA; POTASSIUM CHANNEL KCNJ5; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ALDOSTERONE RELEASE; ANIMAL CELL; ARTICLE; CODING; FEMALE; HETEROZYGOSITY; HUMAN; HUMAN CELL; MISSENSE MUTATION; NONHUMAN; OOCYTE; PATHOPHYSIOLOGY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM CURRENT; XENOPUS;

ADRENAL CORTEX; KCNJ5, POTASSIUM CHANNEL; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; ALDOSTERONE; AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; COHORT STUDIES; FEMALE; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; OOCYTES; PATCH-CLAMP TECHNIQUES; POLYMORPHISM, SINGLE NUCLEOTIDE; XENOPUS LAEVIS;

EID: 84897054016     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02234     Document Type: Article

References (29)

1. Gordon RD, Stowasser M. Primary aldosteronism: the case for screening. Nat Clin Pract Nephrol. 2007;3:582-583.
2. Rossi GP. A comprehensive review of the clinical aspects of primary aldo-steronism. Nat Rev Endocrinol. 2011;7:485-495.
3. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.
4. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from fve continents. J Clin Endocrinol Metab. 2004;89:1045-1050.
5. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 1999;84:4341-4344.
6. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262-265.
7. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768-772.
8. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki P, Stratakis CA, Chrousos GP. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012;97:E1532-E1539.
9. Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A, Wang WH, Lifton RP. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci USA. 2012;109:2533-2538.
10. Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat Rev Endocrinol. 2013;9:104-112.
11. Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, Brown MJ, O'Shaughnessy KM. Somatic mutations affecting the selectivity flter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension. 2012;59:587-591.
12. Åkerström T, Crona J, Delgado Verdugo A, et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity flter. PLoS One. 2012;7:e41926.
13. Murthy M, Cope G, O'Shaughnessy KM. The acidic motif of WNK4 is crucial for its interaction with the K channel ROMK. Biochem Biophys Res Commun. 2008;375:651-654.
14. Cope G, Murthy M, Golbang AP, Hamad A, Liu CH, Cuthbert AW, O'Shaughnessy KM. WNK1 affects surface expression of the ROMK potassium channel independent of WNK4. J Am Soc Nephrol. 2006;17:1867-1874.
15. Murthy M, Azizan EA, Brown MJ, O'Shaughnessy KM. Characterization of a novel somatic KCNJ5 mutation delI157 in an aldosterone-producing adenoma. J Hypertens. 2012;30:1827-1833.
16. He C, Yan X, Zhang H, Mirshahi T, Jin T, Huang A, Logothetis DE. Identifcation of critical residues controlling G protein-gated inwardly rectifying K+ channel activity through interactions with the βγ subunits of G proteins. J Biol Chem. 2002;277:6088-6096.
17. Yamada M, Inanobe A, Kurachi Y. G protein regulation of potassium ion channels. Pharmacol Rev. 1998;50:723-760.
18. Brenner T, O'Shaughnessy KM. Both TASK-3 and TREK-1 two-pore loop K channels are expressed in H295R cells and modulate their membrane potential and aldosterone secretion. Am J Physiol Endocrinol Metab. 2008;295:E1480-E1486.
19. Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology. 2012;153:1774-1782.
20. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeosta-sis. Steroids. 1995;60:48-51.
21. Li NF, Li HJ, Zhang DL, Zhang JH, Yao XG, Wang HM, Abulikemu S, Zhou KM, Zhang XY. Genetic variations in the KCNJ5 gene in primary aldosteronism patients from Xinjiang, China. PLoS One. 2013;8:e54051.
22. Parmar J, Key RE, Rainey WE. Development of an adrenocorticotropin- responsive human adrenocortical carcinoma cell line. J Clin Endocrinol Metab. 2008;93:4542-4546.
23. Rainey WE, Saner K, Schimmer BP. Adrenocortical cell lines. Mol Cell Endocrinol. 2004;228:23-38.
24. McCoy JG, Nimigean CM. Structural correlates of selectivity and inactivation in potassium channels. Biochim Biophys Acta. 2012;1818:272-285.
25. Bichet D, Grabe M, Jan YN, Jan LY. Electrostatic interactions in the channel cavity as an important determinant of potassium channel selectivity. Proc Natl Acad Sci USA. 2006;103:14355-14360.
26. Bichet D, Lin YF, Ibarra CA, Huang CS, Yi BA, Jan YN, Jan LY. Evolving potassium channels by means of yeast selection reveals structural elements important for selectivity. Proc Natl Acad Sci USA. 2004;101:4441-4446.
27. Ludwig A, Zong X, Jeglitsch M, Hofmann F, Biel M. A family of hyperpolarization-activated mammalian cation channels. Nature. 1998;393:587-591.
28. Isomoto S, Kondo C, Kurachi Y. Inwardly rectifying potassium channels: their molecular heterogeneity and function. Jpn J Physiol. 1997;47:11-39.
29. Whorton MR, MacKinnon R. Crystal structure of the mammalian GIRK2 K+ channel and gating regulation by G proteins, PIP2, and sodium. Cell. 2011;147:199-208.